Back Hepatitis C

Hepatitis C

AASLD Liver Meeting Starts this Weekend in Boston

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.

alt

Opioid Maintenance Therapy Linked to Lower Hepatitis C Rates for People Who Inject Drugs

Young drug injectors who undergo opioid agonist maintenance therapy using buprenorphine or methadone have a lower likelihood of becoming infected with hepatitis C virus (HCV) than those who continue injecting or use other types of substance use treatment, according to a study published in the October 27 edition of JAMA Internal Medicine.

alt

HCV Sexual Transmission: HIV Negative May Be at Risk, More Awareness and Testing Needed

Hepatitis C virus (HCV) is known to be sexually transmitted among HIV positive men who have sex with men, but HIV negative men may be at risk as well, according to recent reports. Other recent studies have looked at awareness of HCV sexual transmission and screening practices, suggesting that improvement is needed in both areas.

alt

IDWeek 2014: Age, Sex, and Race Predict Spontaneous Hepatitis C Virus Clearance

African-Americans, men, and older people were less likely to experience natural hepatitis C virus (HCV) clearance without treatment, according to findings presented at IDWeek 2014 last week in Philadelphia. Overall, out of more than 1000 people with newly reported HCV infection, 15% spontaneously cleared the virus.

alt

Simeprevir as Effective, Better Tolerated than Telaprevir in HCV Triple Therapy

The recently approved next-generation hepatitis C virus (HCV) protease inhibitor simeprevir (Olysio) produced sustained virological response rates similar to those of telaprevir (Incivek or Incivo) when combined with pegylated interferon and ribavirin, but with fewer side effects, researchers reported at theViral Hepatitis Congress taking place this week in Frankfurt.

alt

IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

alt

FDA Approves Harvoni, Gilead's Sofosbuvir/Ledipasvir Combo Pill for Hepatitis C

alt

On October 10, the U.S. Food and Drug Administration (FDA) approved a new once-daily combination pill for the treatment of genotype 1 chronic hepatitis C containing Gilead Sciences' HCV nucleotide polymerase inhibitor sofosbuvir (Sovaldi) plus ledipasvir, the first approved HCV NS5A inhibitor.

IDWeek 2014: Sofosbuvir/Ledipasvir Safe and Effective for Genotype 1 HCV

A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir -- the combination in Gilead Science's recently approved Harvoni pill -- was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, researchers reported at the IDWeek 2014 meeting last week in Philadelphia.

alt

BMS Withdraws FDA Application for Hepatitis C Drug Asunaprevir

Bristol-Myers Squibb unexpectedly announced this week that it will no longer seek U.S. Food and Drug Administration (FDA) approval for its experimental hepatitis C virus (HCV) protease inhibitor asunaprevir, despite promising results in clinical trials to date.

alt